Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

NCT03814746 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease (SCD)

Interventions

DRUG: Crizanlizumab (SEG101)
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals